Candex

NDA 50233, held by Bayer Pharms. Nystatin.

As of Nov 13, 2026, NDA 50233 (Candex), held by Bayer Pharms, was not approved, with 0 approved supplements and 0 published complete response letters.

• First approved: Not approved
• Supplements approved: 0
• Complete response letters: 0

Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters